Dermatology · Monterey Park, CA
NPI
1518426766
Since 2019
Specialty
Dermatology
Code 207N00000X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
616 N Garfield Ave Ste 203
Monterey Park, CA, 91754
Phone (626) 635-1688
Groups this clinician bills Medicare through
Medicare paid, 2024
$925K
9,742 services
Medicare patients, 2024
732
Average age 75
Drug cost, 2024
$1.2M
8,379 prescriptions
Company payments, 2025
$1,980
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Calvin T Sung was code 96910 (skin), 2,971 times for 258 patients. In total Calvin T Sung billed 9,742 services in 101 codes, and Medicare paid $925K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2023-07-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 96910 Skin | Office | 2,971 | 258 | $110.10 | $327K |
| J3301 Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 1,419 | 148 | $0.80 | $1,134 |
| 99213 Office E&M - Established | Office | 993 | 451 | $77.30 | $77K |
| 96920 Skin | Office | 949 | 83 | $139.29 | $132K |
| 17110 Destruction Skin Lesion | Office | 550 | 303 | $96.78 | $53K |
| 99203 Office E&M - New | Office | 372 | 372 | $83.49 | $31K |
| 99214 Office E&M - Established | Office | 324 | 228 | $108.70 | $35K |
| 99204 Office E&M - New | Office | 241 | 241 | $134.19 | $32K |
| 17003 Destruction Skin Lesion | Office | 238 | 47 | $6.05 | $1,440 |
| 11901 Skin | Office | 185 | 88 | $45.81 | $8,475 |
| 17000 Destruction Skin Lesion | Office | 166 | 125 | $39.28 | $6,520 |
| 11102 Skin Biopsy | Office | 161 | 144 | $69.11 | $11K |
| 97610 Skin | Office | 136 | 11 | $397.93 | $54K |
| 11900 Skin | Office | 135 | 80 | $41.63 | $5,621 |
| 17004 Destruction Skin Lesion | Office | 90 | 60 | $147.87 | $13K |
By year: 2023 $282K for 2,459 services; 2024 $925K for 9,742 services.
Medicare prescription drug claims, 2024
In 2024, the drug Calvin T Sung prescribed most often to Medicare patients was Ketoconazole, with 1,516 prescriptions and refills. In total Calvin T Sung wrote 8,379 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Ketoconazole Generic | 1,516 | 2,107 | 580 | $32K |
| Triamcinolone Acetonide Generic | 1,214 | 1,294 | 657 | $24K |
| Clobetasol Propionate Generic | 799 | 1,027 | 353 | $46K |
| Mupirocin Generic | 753 | 821 | 493 | $6,390 |
| Hydrocortisone Generic | 534 | 581 | 312 | $4,146 |
| Betamethasone Diprop Augmented Betamethasone/Propylene Glyc | 462 | 839 | 285 | $56K |
| Doxycycline Hyclate Generic | 460 | 499 | 333 | $2,949 |
| Fluocinonide Generic | 338 | 580 | 188 | $24K |
| Econazole Nitrate Generic | 219 | 293 | 99 | $8,567 |
| Diflorasone Diacetate Generic | 177 | 243 | 87 | $131K |
| Nystatin Generic | 175 | 235 | 94 | $2,853 |
| Ciclopirox Generic | 169 | 204 | 80 | $3,495 |
| Mometasone Furoate Generic | 167 | 240 | 77 | $7,465 |
| Ciclopirox Ciclopirox Olamine | 134 | 263 | 90 | $4,023 |
| Clindamycin Phosphate Generic | 116 | 191 | 64 | $4,599 |
Brand drugs: - claims; generic drugs: 8,188 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Calvin T Sung $1,980 ($1,980 in general payments such as food, travel and fees) from 18 companies. The largest payer was Genzyme Corporation with $300.
| Company | Payments | Amount |
|---|---|---|
| Genzyme Corporation SNY | 10 | $300 |
| Novartis Pharmaceuticals Corporation NVS | 12 | $245 |
| Amgen Inc. AMGN | 14 | $236 |
| Regeneron Healthcare Solutions, Inc. REGN | 6 | $214 |
| Incyte Corporation INCY | 9 | $180 |
| Abbvie Inc. ABBV | 10 | $162 |
| Galderma Laboratories, L.P. GALD.SW | 5 | $118 |
| LEO Pharma Inc. | 4 | $84.18 |
| Sanofi-Aventis U.S. LLC SNY | 1 | $72 |
| Arcutis Biotherapeutics, Inc. ARQT | 3 | $65.36 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.